Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - Additional analyses provided to the FDA, which were intended to show improved Overall Survival, were also unlikely to satisfy FDA requirements for the Iomab-B BLA [2]. - The lawsuit suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements related to the company's drug approval process [1][2]. Group 1: Allegations - The complaint alleges that during the class period from October 31, 2022, to August 2, 2024, the defendants made materially false and misleading statements regarding the Phase 3 Sierra trial data [2]. - It is claimed that the data from the Sierra trial was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - The additional analyses provided to the FDA to support the Sierra trial's poor overall survival data were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - The defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is May 27, 2025, and they are encouraged to register promptly [3]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025 [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by May 26, 2025 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [4] Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding its Iomab-B Biologics License Application (BLA) and the likelihood of FDA approval [5] - Specific claims include that data from the Sierra Trial was unlikely to meet FDA guidelines, and as a result, the FDA might refuse to review the BLA or deny approval [5] - The lawsuit asserts that the defendants' positive statements about Actinium's business and prospects were materially misleading [5]

Core Viewpoint - A federal securities class action has been filed against Actinium Pharmaceuticals, with a deadline for investors to seek lead plaintiff status by May 27, 2025, related to securities acquired between October 31, 2022, and August 2, 2024 [1]. Group 1: Company Developments - On August 5, 2024, Actinium announced a regulatory update regarding its Biologics License Application (BLA) for lomab-B, revealing that the FDA required an additional clinical study to support the BLA filing [3]. - Following the announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2024 [3]. Group 2: Legal Allegations - The complaint alleges that during the Class Period, Actinium misled the market regarding the likelihood of its BLA data meeting FDA guidelines for acceptance and approval [4].

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - Additional analyses provided to the FDA, which suggested improved Overall Survival, were also claimed to be insufficient to satisfy FDA requirements for Iomab-B BLA approval [2]. - The lawsuit indicates that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were alleged to be materially misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Actinium during the specified timeframe have until May 27, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is May 26, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been ranked highly for securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding the likelihood of FDA approval for its Iomab-B Biologics License Application [5] - Specific claims include that data from the Sierra Trial was unlikely to meet FDA guidelines, and that positive statements made by Actinium were materially misleading [5]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Actinium Pharmaceuticals, Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's Iomab-B BLA application to the FDA [1][2]. Group 1: Allegations - The complaint alleges that during the class period from October 31, 2022, to August 2, 2024, the defendants made materially false and misleading statements regarding the Phase 3 Sierra trial data [2]. - It is claimed that the data from the Sierra trial was unlikely to meet FDA guidelines for the acceptance and approval of the Iomab-B BLA [2]. - Additional analyses provided to the FDA to mitigate poor overall survival data from the Sierra trial were also unlikely to satisfy FDA requirements [2]. - As a result of these issues, the FDA was expected to refuse to review the Iomab-B BLA or find it unlikely to approve the application in its current form [2]. - The defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 27, 2025, to participate in the case [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. - There is no cost or obligation for shareholders to participate in this class action [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Summary by Sections Class Action Details - The lawsuit aims to recover losses for investors who were misled by false statements regarding the company's Phase 3 Sierra trial data and its implications for the FDA approval of the targeted radiotherapy, Iomab-B BLA [2]. - Allegations include that the data from the Sierra trial was unlikely to meet FDA guidelines, and additional analyses provided to the FDA were also unlikely to satisfy approval requirements [2]. Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action securities lawsuit has been filed against Actinium Pharmaceuticals, alleging securities fraud that negatively impacted investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - It is alleged that additional analyses provided to the FDA, intended to show improved Overall Survival, were also unlikely to satisfy FDA requirements for Iomab-B BLA approval [2]. - The lawsuit suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Actinium during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Actinium Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - Additional analyses provided to the FDA, which were intended to show improved Overall Survival, were also unlikely to satisfy FDA requirements for the Iomab-B BLA [2]. - The lawsuit suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].